NLR family pyrin domain containing 5Genealiases: CLR19.8 · MATER · NALP5 · OZEMA19 · PAN11 · PYPAF8
Q-omics provides the consensus-scored NLRP5 profile across patient tissues and cancer cell-line models. NLRP5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NLRP5 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, NLRP5 RNA expression shows 6,631 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, HNSC, and STAD as cancer lineages where NLRP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRP5 survival associations across molecular data types. NLRP5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRP5 RNA expression–survival associations across cancer types. High NLRP5 expression shows unfavorable associations in LIHC, KIRC, KICH, MESO, LUSC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NLRP5 RNA expression.
This table summarizes NLRP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NLRP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRP5 shows lower tumor expression in BRCA and higher tumor expression in HNSC, UCEC, PRAD, CHOL and LIHC. The HNSC box plot shows higher NLRP5 RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .004).
This table shows molecular features associated with NLRP5 in patient tissues and cancer cell lines. In patient samples, NLRP5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
